ACCORD Study Group et al. (2010). Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med, 362, 1575–85.Google Scholar

Blood Pressure Lowering Treatment Trialists’ Collaboration. (2003). Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 362, 1527–35.Google Scholar

Boan, AD, Lackland, DT, Ovbiagele, B. (2014). Lowering of blood pressure for recurrent stroke prevention. Stroke, 45, 2506–13.Google Scholar

Brunström, M, Carlberg, B. (2018). Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med, 178(1), 28–36.Google Scholar

Collins, R, Peto, R, MacMahon, S, Hebert, P, Fiebach, NH, Eberlein, KA, et al. (1990). Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 335(8693), 827–38.Google Scholar

Ettehad, D, Emdin, CA, Kiran, A, Anderson, SG, Callender, T, Emberson, J, et al. (2016). Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, 387(10022), 957–67.CrossRefGoogle Scholar

Huang, Y, Cai, X, Li, Y, Su, L, Mai, W, Wang, S, et al. (2014). Prehypertension and the risk of stroke: a meta-analysis. Neurology, 82, 1153–61.Google Scholar

Kim, S, Shin, DW, Yun, JM, Hwang, Y, Park, SK, Ko, YJ, et al. (2016). Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension, 67, 506–12.CrossRefGoogle ScholarPubMed

Law, MR, Morris, JK, Wald, NJ. (2009). Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, b1665. doi:10.1136/bmj.b1665.CrossRefGoogle ScholarPubMed

Lee, M, Saver, JL, Chang, B, Chang, KH, Hao, Q, Ovbiagele, B, et al. (2011). Presence of baseline prehypertension and risk of incident stroke: a meta-analysis. Neurology, 77, 1330–1337.Google Scholar

Lee, M, Saver, JL, Hong, K-S, Hao, Q, Ovbiagele, B. (2012). Does achieving an intensive versus usual blood pressure level prevent stroke? Ann Neurol, 71, 133–140.Google Scholar

Liu, L, Wang, Z, Gong, L, Zhang, Y, Thhijs, L, Staessen, JA, et al. (2009). Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res, 32, 1032–40.CrossRefGoogle Scholar

MacMahon, S, Peto, R, Cutler, J. (1990). Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 335, 765–74.Google Scholar

Perkovic, V, Rodgers, A. (2015). Redefining blood-pressure targets – SPRINT starts the marathon. N Engl J Med, 373, 2175–8.Google Scholar

PROGRESS Collaborative Group. (2001). Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358, 1033–41.Google Scholar

Sardana, M, Syed, AA, Hashmath, Z, Phan, TS, Koppula, MR, Kewan, U, et al. (2017). Beta-blocker use is associated with impaired left atrial function in hypertension. J Am Heart Assoc, 6. doi:10.1161/JAHA.116.005163.Google Scholar

Sipahi, I, Swaminathan, A, Natesan, V, Debanne, SM, Simon, DI, Fang, JC. (2012). Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials. Stroke, 43, 432–40.CrossRefGoogle Scholar

SPRINT MIND Investigators for the SPRINT Research Group. (2019). Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA, 322, 169–70.Google Scholar

SPRINT Research Group et al. (2015). A randomized trial of intensive versus standard blood-pressure control. N Engl J Med, 373, 2103–16.Google Scholar

Sundstrom, J, Arima, H, Jackson, R, Turnbull, F, Rahimi, K, Chalmers, J, et al. (2015). Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med, 162, 184–91.CrossRefGoogle ScholarPubMed

Turner, GM, Calvert, M, Feltham, MG, Ryan, R, Fitzmaurice, D, Cheng, KK, et al. (2016). Under-prescribing of prevention drugs and primary prevention of stroke and transient ischaemic attack in UK general practice: a retrospective analysis. PLoS Med, 13, e1002169.CrossRefGoogle ScholarPubMed

Whelton, PK, Carey, RM, Aronow, WS, Casey, DE Jr, Collins, KJ, Dennison Himmelfarb, C, et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71(6), e13–e115.Google Scholar

Zonneveld, TP, Richard, E, Vergouwen, MD, Nederkoorn, PJ, de Haan, R, Roos, YB, et al. (2018). Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev, 7. CD007858. doi:10.1002/14651858.CD007858.pub2.Google Scholar

Acheson, J, Hutchinson, EC. (1972). Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis, 15, 177–83.CrossRefGoogle ScholarPubMed

Adams, SP, Sekhon, SS, Wright, JM. (2014). Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev, 11. CD010254.Google ScholarPubMed

Adams, SP, Tsang, M, Wright, JM. (2015). Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev, 3. CD008226Google Scholar

Amarenco P, Kim JS, Labreuche J, et al. (2020). A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med, 382, 9–19.Google Scholar

Amarenco, P, Labreuche, J. (2009). Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol, 8, 453–63.Google Scholar

Battaggia, A, Donzelli, A, Font, M, Molteni, D, Galvano, A. (2015). Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 10, e0124587.Google Scholar

Bays, H. (2006). Statin safety: an overview and assessment of the data – 2005. Am J Cardiol, 97(suppl), 6 C–26 C.Google Scholar

Bezerra, DC, Sharrett, AR, Matsushita, K, Gottesman, RF, Shibata, D, Mosley, TH Jr, et al. (2012). Risk factors for lacunar subtype in the atherosclerosis risk in Communities (ARIC) Study. Neurology, 78, 102–108.Google Scholar

Bhatia, M, Howard, SC, Clarke, TG, Murphy, MFG, Rothwell, PM. (2004). Apo-lipoproteins predict ischaemic stroke in patients with a previous transient ischaemic attack. Presented at the World Stroke Congress, Vancouver, Canada.Google Scholar

Cholesterol Treatment Trialists’ (CTT) Collaboration. (2005). Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366, 1267–78.Google Scholar

Cholesterol Treatment Trialists’ (CTT) Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet, 376, 1670–81.Google Scholar

Cholesterol Treatment Trialists’ (CTT) Collaboration. (2012). The effect of lowering LDL-cholesterol with statin therapy in people at low risk of vascular disese: meta-analysis of individual data from 27 randomised trials. Lancet, 380, 581–90.Google Scholar

Cholesterol Treatment Trialists’ (CTT) Collaboration. (2015). Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised studies. Lancet, 385, 1397–1405.Google Scholar

Collins, R, Reith, C, Emberson, J, Armitage, J, Baigent, C, Blackwell, L, et al. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 388(10059), 2532–61.Google Scholar

Dale, KM, Coleman, CI, Henyan, NN, Kluger, J, White, CM. (2006). Statins and cancer risk. JAMA, 295, 74–80.Google Scholar

Di Mascio, R, Marchioli, R, Tognoni, G. (2000). Cholesterol reduction and stroke occurrence: an overview of randomised clinical trials. Cerebrovasc Dis, 10, 85–92.Google Scholar

Heart Protection Study Collaborative Group. (2011). Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomized controlled trial. Lancet, 578, 2013–20.Google Scholar

Hopper, L, Martin, N, Abpelhamid, A, Davey Smith, G. (2015). Reduced in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev, 6. CD011737.Google Scholar

HPS2-THRIVE Collaborative Group. (2014). Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med, 371, 203–12.Google Scholar

HPS3/TIMI55–REVEAL Collaborative Group. (2017). Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med, 377(13), 1217–27Google Scholar

Imamura, T, Doi, Y, Arima, H, Yonemoto, K, Hata, J, Kubo, M, et al. (2009). LDL-cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population. Stroke, 40, 382–8.CrossRefGoogle Scholar

Keene, D, Price, C, Shun-Shin, MJ, Francis, DP. (2014). Effect on cardiovascular risk of high density lipoprotein targeted drug treatment niacin, fibrates, and CEPT inhibitors: meta-analysis of randomized controlled trials including 117,411 patients. BMJ, 349, 1–14.Google Scholar

Koren-Morag, N, Tanne, D, Graff, E, Goldbourt, U, for the Bezafibrate Infarction Prevention Study Group. (2002). Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease. The Bezafibrate Infarction Prevention Registry . Arch Int Med, 162, 993–9.Google Scholar

Law, MR, Wald, NJ, Rudnicka, AR. (2003). Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ, 326, 1423–9.CrossRefGoogle ScholarPubMed

Leppala, JM, Virtamo, J, Fogelholm, R, Albanes, D, Heinonen, OP. (1999). Different risk factors for different stroke subtypes. Stroke, 30, 2535–40.Google Scholar

Lewington, S, Whitelock, G, Clarke, R, Sherliker, P, Emberson, J, Halsey, J, et al. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 370, 1829–39.Google Scholar

Lp-PLA₂ Studies Collaboration. (2010). Lipoprotein-associated phospholipase A₂ and risk of coronary disease, stroke and mortality: collaborative analysis of 32 prospective studies. Lancet, 375, 1536–44.Google Scholar

Manktelow, B, Gillies, C, Potter, JF. (2002). Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev, 3. CD002091. doi:10.1002/14651858.CD002091.Google Scholar

McKinney, JS, Kostis, WJ. (2012). Statin therapy and risk of intracerebral hemorrhage. A meta-analysis of 31 randomized controlled trials. Stroke, 43, 2149–56.Google Scholar

Nagasawa, S, Okamura, T, Iso, H, Tamakoshi, A, Yarada, M, Watanabe, M, et al. (2012). Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65,594 individuals from cohort studies in Japan. J Am Heart Assoc, 1, e001974.CrossRefGoogle Scholar

Orozco-Beltran, D, Gil-Guillen, VF, Redon, J, Martin-Moreno, JM, Pallares-Carratala, V, Navarro-Perez, J, et al.; ESCARVAL Study Group. (2017). Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: the ESCARVAL-RISK study. PLoS One, 12(10), e0186196.Google Scholar

Paciaroni, M, Hennerici, M, Agnelli, G, Bogousslavsky, J. (2007). Statins and stroke prevention. Cerebrovasc Dis, 24, 170–82.Google Scholar

Peto, R, Collins, R. (2018). Trust the blinded randomized evidence that statin therapy rarely causes symptomatic side effects. Circulation, 138(15), 1499–1501.Google Scholar

Pikula, A, Belser, AS, Wang, J, Himali, JJ, Kelly-Haynes, M, Kase, CS, et al. (2015). Lipid and lipoprotein measurement and the risk of ischemic vascular events. Framingham Study. Neurology, 84, 472–9.Google Scholar

Plehn, JF, Davis, BR, Sacks, FM, Rouleau, JL, Pfeffer, MA, Bernstein, V, et al. (1999). Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The CARE Investigators. Circulation, 99, 216–23.Google Scholar

Preiss, D, Seshasai, SR, Welsh, P, Murphy, SA, Ho, JE, Waters, DD, et al. (2011). Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA, 305, 2556–64.Google Scholar

Prospective Studies Collaboration. (1995). Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet, 346, 1647–53.Google Scholar

Sabatine, MS, Giugliano, RP, Keech, AC, Honarpour, N, Wiviott, SD, Murphy, SA, et al.; FOURIER Steering Committee and Investigators. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 376(18), 1713–22.Google Scholar

Sabatine, MS, Wiviott, SD, Im, K, Murphy, SA, Giugliano, RP. (2018). Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol, 3(9), 823–8.CrossRefGoogle ScholarPubMed

Sattar, N, Preiss, D, Murray, HM, Welsh, P, Buckley, BM, de Craen, AJ, et al. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet, 375, 735–42.Google Scholar

Savarese, G, De Ferrari, GM, Rosano, GM, Perrone-Filardi, P. (2015). Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol, 10(201), 247–52.Google Scholar

Schandelmaier, S, Briel, M, Saccilotto, R, Olu, KK, Arpagaus, A, Hemkens, LG, et al. (2017). Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev, 6. CD009744.Google Scholar

Silverman, MG, Ference, BA, Im, K, Wiviott, SD, Giugliano, RP, Grundy, SM, et al. (2016). Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA, 316(12), 1289–97.Google Scholar

Simons, LA, Simons, J, Friedlander, Y, McCallum, J. (2001). Cholesterol and other lipids predict CHD and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis, 159, 201–08.Google Scholar

SPARCL Investigators. (2006). High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 355, 549–59.Google Scholar

Tanaka, T, Tomonori, O. (2012). Blood cholesterol level and risk of stroke in Community-based or Worksite cohort studies: a review of Japanese Cohort Studies in the past 20 years. Keio J Med, 81, 79–88.Google Scholar

Taylor, F, Huffman, MD, Macedo, AF, Moore, TH, Burke, M, Davey Smith, G, et al. (2013). Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 1. CD004816.Google Scholar

Teng, M, Lin, L, Zhao, YJ, Khoo, AL, Davis, BR, Yong, QW. (2015). Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. Drugs Aging, 32(8), 649–61.Google Scholar

Thompson, PD, Clarkson, P, Karas, RH. (2003). Statin associated myopathy. JAMA, 289, 1681–90.CrossRefGoogle ScholarPubMed

van Driel, ML, Morledge, MD, Ulep, R, Shaffer, JP, Davies, P, Deichmann, R. (2016). Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev, 12. CD004371.Google ScholarPubMed

Veterans Administration Cooperative Study Group. (1973). The treatment of cerebrovascular disease with Clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke, 4, 684–93.Google Scholar

Wang, D, Liu, B, Tao, W, Hao, Z, Liu, M. (2015). Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev, 10. CD009580.Google Scholar

Wang, X, Dong, Y, Qi, X, Huang, C, Hou, L. (2013). Cholesterol levels and risk of hemorrhagic stroke. A systematic review and meta-analysis. Stroke, 44, 1833–9.Google Scholar

White, HD, Simes, RJ, Anderson, NE, Hankey, GJ, Watson, JDG, Hunt, D, et al. (2000). Pravastatin therapy and the risk of stroke. N Engl J Med, 343, 317–26.CrossRefGoogle ScholarPubMed

Zhan, S, Tang, M, Liu, F, Xia, P, Shu, M, Wu, X. (2018). Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev, 11. CD012502.Google Scholar

Zhang, XL, Zhu, QQ, Zhu, L, Chen, JZ, Chen, QH, Li, GN, et al. (2015). Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med, 13, 123. doi:10.1186/s12916.Google Scholar

Zhang, Y, Tuomilehto, J, Jousilahti, P, Wang, Y, Antikainen, R, Hu, G. (2012). Total and high-density lipoprotein cholesterol and stroke risk. Stroke, 4, 1768–74.Google Scholar

Aburto, NJ, Ziolkovska, A, Hooper, L, Elliott, P, Cappuccio, FP, Meerpohl, JJ. (2013). Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ, 346, f1326.Google Scholar

Adebamowo, SN, Spiegelman, D, Willett, WC, Rexrode, KM. (2015). Association between intakes of magnesium, potassium, and calcium and risk of stroke: 2 cohorts of US women and updated meta-analyses. Am J Clin Nutr, 101(6), 1269–77.Google Scholar

Adler, AJ, Taylor, F, Martin, N, Gottlieb, S, Taylor, RS, Ebrahim, S. (2014). Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev, 12. CD009217.Google Scholar

Afshin, A, Micha, R, Khatibzadeh, S, Mozaffarian, D. (2014). Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis. Am J Clin Nutr, 100(1), 278–88.Google Scholar

Anthenelli, RM, Benowitz, NL, West, R, St Aubin, L, McRae, T, Lawrence, D, et al. (2016). Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 387(10037), 2507–20.Google Scholar

Antithrombotic Trialists, C. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324(7329), 71–86.Google Scholar

Antithrombotic Trialists, Collaboration, Baigent, C Blackwell, L, Collins, R, Emberson, J, Godwin, J, Peto, R, et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678), 1849–60.Google Scholar

Aune, D, Giovannucci, E, Boffetta, P, Fadnes, LT, Keum, N, Norat, T, et al. (2017). Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies. Int J Epidemiol, 46(3), 1029–56.Google Scholar

Aune, D, Keum, N, Giovannucci, E, Fadnes, LT, Boffetta, P, Greenwood, DC, et al. (2016a). Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies. BMC Med, 14(1), 207.Google Scholar

Aune, D, Keum, N, Giovannucci, E, Fadnes, LT, Boffetta, P, Greenwood, DC, et al. (2016b). Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. BMJ, 353, i2716.Google Scholar

Aung, T, Halsey, J, Kromhout, D, Gerstein, HC, Marchioli, R, Tavazzi, L, et al., and Omega-3 Treatment Trialists. (2018). Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol, 3(3), 225–34.Google Scholar

Avert Trial Collaboration Group. (2015). Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet, 386(9988), 46–55.Google Scholar

Baliunas, DO, Taylor, BJ, Irving, H, Roerecke, , Patra, J, Mohapatra, S, et al. (2009). Alcohol as a risk factor for type 2 diabetes: A systematic review and meta-analysis. Diabetes Care, 32(11), 2123–32.Google Scholar

Bath, PM, Gray, LJ. (2005). Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ, 330(7487), 342.Google Scholar

Bazerbachi, F, Haffar, S, Sawas, T, Vargas, EJ, Kaur, RJ, Wang, Z, et al. (2018). Fluid-filled versus gas-filled intragastric balloons as obesity interventions: a network meta-analysis of randomized trials. Obes Surg, 28(9), 2617–25.Google Scholar

Benowitz, NL, Pipe, A, West, R, Hays, JT, Tonstad, S, McRae, T, et al. (2018). Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med, 178(5), 622–31.Google Scholar

Bernhardt, J, Churilov, L, Ellery, F, Collier, J, Chamberlain, J, Langhorne, P, et al., and A. C. Group (2016). Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT). Neurology, 86(23), 2138–45.Google Scholar

Bhat, VM, Cole, JW, Sorkin, JD, Wozniak, MA, Malarcher, AM, Giles, WH, et al. (2008). Dose-response relationship between cigarette smoking and risk of ischemic stroke in young women. Stroke, 39(9), 2439–43.Google Scholar

Bhatnagar, A, Whitsel, LP, Ribisl, KM, Bullen, C, Chaloupka, F, Piano, MR, et al.; American Heart Association Advocacy Coordinating Committee, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research. (2014). Electronic cigarettes: a policy statement from the American Heart Association. Circulation, 130(16), 1418–36.Google Scholar

Billinger, SA, Arena, R, Bernhardt, J, Eng, JJ, Franklin, BA, Johnson, CM, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Clinical Cardiology. (2014). Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45(8), 2532–53.Google Scholar

Bjelakovic, G, Nikolova, D, Gluud, LL, Simonetti, RG, Gluud, C. (2012). Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev, 3. CD007176.Google Scholar

Boardman, HM, Hartley, L, Eisinga, A, Main, C, Roque i Figuls, M, Bonfill Cosp, X, et al. (2015). Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev, 3. CD002229.Google Scholar

Borek, AJ, Abraham, C, Greaves, CJ, Tarrant, M. (2018). Group-based diet and physical activity weight-loss interventions: a systematic review and meta-analysis of randomised controlled trials. Appl Psychol Health Well Being, 10(1), 62–86.Google Scholar

Briasoulis, A, Agarwal, V, Messerli, FH. (2012). Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. J Clin Hypertens (Greenwich), 14(11), 792–8.Google Scholar

Brien, SE, Ronksley, PE, Turner, BJ Mukamal, KJ, Ghali, WA. (2011). Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ, 342, d636.Google Scholar

Brunstrom, M, Carlberg, B. (2016). Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, 352, i717.Google Scholar

Cahill, K, Lindson-Hawley, N, Thomas, KH, Fanshawe, TR, Lancaster, T. (2016). Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 5. CD006103.Google Scholar

Cahill, K, Stevens, S, Perera, R, Lancaster, T. (2013). Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev, 5. CD009329.Google Scholar

Cai, X, Wang, C, Wang, S, Cao, G, Jin, C, Yu, J, et al. (2015). Carbohydrate intake, glycemic index, glycemic load, and stroke: a meta-analysis of prospective cohort studies. Asia Pac J Public Health, 27(5), 486–96.Google Scholar

Chan, WS., Ray, J, Wai, EK, Ginsburg, S, Hannah, ME, Corey, PN, et al. (2004). Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med, 164(7), 741–7.Google Scholar

Chang, CL, Donaghy, M, Poulter, N. (1999). Migraine and stroke in young women: case-control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ, 318(7175), 13–18.Google Scholar

Chang, SH, Stoll, CR, Song, J, Varela, JE, Eagon, CJ, Colditz, GA. (2014). The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg, 149(3), 275–87.Google Scholar

Chen, Y, Copeland, WK, Vedanthan, R, Grant, E, Lee, JE, Gu, D, et al. (2013). Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ, 347, f5446.Google Scholar

Cheng, P, Huang, W, Bai, W, Wu, Y, Yu, J, Zhu, X, et al. (2015). BMI affects the relationship between long chain n-3 polyunsaturated fatty acid intake and stroke risk: a meta-analysis. Sci Rep, 5, 14161.CrossRefGoogle ScholarPubMed

Cholesterol Treatment Trialists, Kearney, PM, Blackwell, L, Collins, R, Keech, A, Simes, J, Peto, R, et al. (2008). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 371(9607), 117–25.Google Scholar

Chowdhury, R, Stevens, S, Gorman, D, Pan, A, Warnakula, S, Chowdhury, S, et al. (2012). Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ, 345, e6698.Google Scholar

D’Elia, L, Iannotta, C, Sabino, P, Ippolito, R. (2014). Potassium-rich diet and risk of stroke: updated meta-analysis. Nutr Metab Cardiovasc Dis, 24(6), 585–7.Google Scholar

D’Isabella, NT, Shkredova, DA, Richardson, JA, Tang, A. (2017). Effects of exercise on cardiovascular risk factors following stroke or transient ischemic attack: a systematic review and meta-analysis. Clin Rehabil, 31(12), 1561–72.Google Scholar

de Goede, J, Soedamah-Muthu, SS, Pan, A Gijsbers, L, Geleijnse, M. (2016). Dairy consumption and risk of stroke: a systematic review and updated dose-response meta-analysis of prospective cohort studies. J Am Heart Assoc, 5(5):e002787. doi: 10.1161/JAHA.115.002787 May 20;5(5):e002787. doi: 10.1161/JAHA.115.002787.CrossRefGoogle ScholarPubMed

de Souza, RJ, Mente, A, Maroleanu, A, Cozma, AI, Ha, V, Kishibe, T, et al. (2015). Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ, 351, h3978.Google Scholar

Ding, M, Bhupathiraj, SN, Satija, A, van Dam, RM, Hu, FU. (2014). Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation, 129(6), 643–59.CrossRefGoogle Scholar

Edjoc, RK, Reid, RD, Sharma, M. (2012). The effectiveness of smoking cessation interventions in smokers with cerebrovascular disease: a systematic review. BMJ Open, 2(6), e002022.Google Scholar

Eisenberg, MJ, Windle, SB, Roy, N, Old, W, Grondin, FR, Bata, I, et al., and EVITA investigators. (2016). Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation, 133(1), 21–30.Google Scholar

Emdin, CA, Rahimi, K, Neal, B, Callender, T, Perkovic, V, Patel, A. (2015). Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA, 313(6), 603–15.Google Scholar

Epstein, KA, Viscoli, CM, Spence, JD, Young, LH, Inzucchi, SE, Gorman, M, et al, and I. T. Investigators. (2017). Smoking cessation and outcome after ischemic stroke or TIA. Neurology, 89(16), 1723–9.Google Scholar

Fang, X, Wang, K, Han, D, He, X, Wei, J, Zhao, L, et al. (2016). Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies. BMC Med, 14(1), 210.Google Scholar

Ferri, M, Amato, L, Davoli, M. (2006). Alcoholics Anonymous and other 12-step programmes for alcohol dependence. Cochrane Database Syst Rev, 3. CD005032.Google Scholar

Ford, JA, MacLennan, GS, Avenell, A, Bolland, M, Grey, A, Witham, M, et al. (2014). Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr, 100(3), 746–55.Google Scholar

Fox, CS, Golden, SH, Anderson, C, Bray, GA, Burke, LE, de Boer, IH, et al.; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. (2015). Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 132(8), 691–718.Google Scholar

Gillum, LA, Mamidipudi, SK, Johnston, SC. (2000). Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA, 284(1), 72–8.Google Scholar

Greaves, CJ, Sheppard, KE, Abraham, C, Hardeman, W, Roden, M, Evans, PH, et al., I. S. Group (2011). Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health, 11, 119.Google Scholar

Guo, Y, Yue, XJ, Li, HH, Song, ZX, Yan, HQ, Zhang, P, et al. (2016). Overweight and obesity in young adulthood and the risk of stroke: a meta-analysis. J Stroke Cerebrovasc Dis, 25(12), 2995–3004.Google Scholar

Hankey, GJ. (2017). The role of nutrition in the risk and burden of stroke: an update of the evidence. Stroke, 48(11), 3168–74.Google Scholar

Harvard Women’s Health Watch (2015). DASH or Mediterranean: which diet is better for you? Harvard Women’s Health Watch, 14(9), 4.Google Scholar

He, Y, Li, Y, Chen, Y, Feng, L, Nie, Z. (2014). Homocysteine level and risk of different stroke types: a meta-analysis of prospective observational studies. Nutr Metab Cardiovasc Dis, 24(11), 1158–65.Google Scholar

Hooper, L, Martin, N, Abdelhamid, A., Davey Smith, G. (2015). Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev, 6. CD011737.Google Scholar

Hopper, I, Billah, B, Skiba, M, Krum, H. (2011). Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil, 18(6), 813–23.Google Scholar

Hsu, CY, Chiu, SW, Hong, KS, Saver, JL, Wu, YL, Lee, JD, et al. (2018). Folic acid in stroke prevention in countries without mandatory folic acid food fortification: a meta-analysis of randomized controlled trials. J Stroke, 20(1), 99–109.Google Scholar

Huang, K, Liu, F, Han, X, Huang, C, Huang, J, Gu, D, et al. (2016). Association of BMI with total mortality and recurrent stroke among stroke patients: A meta-analysis of cohort studies. Atherosclerosis, 253(10), 94–101.Google Scholar

Hughes, JR, Stead, LF, J. Hartmann-Boyce, J, Cahill, K, Lancaster, T. (2014). Antidepressants for smoking cessation. Cochrane Database Syst Rev, 1. CD000031.Google Scholar

James, AH, Bushnell, CD, Jamison, MG, Myers, ER. (2005). Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol, 106(3), 509–16.Google Scholar

Jensen, MD, Ryan, DH, Apovian, CM, Ard, JD Comuzzie, AG, Donato, KA, et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63(25 Pt B): 2985–3023.Google Scholar

Johnston, BC, Kanters, S, Bandayrel, K, Wu, P, Naji, F, Siemieniuk, RA, et al. (2014). Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA, 312(9), 923–933.Google Scholar

Jonas, DE, Amick, HR, Feltner, C, Bobashev, G, Thomas, K, Wines, R, et al. (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA, 311(18), 1889–1900.Google Scholar

Kawachi, I, Colditz, GA, Stampfer, MJ, Willett, WC, Manson, JE, Rosner, B, et al. (1993). Smoking cessation and decreased risk of stroke in women. JAMA, 269(2), 232–6.Google Scholar

Kemmeren, JM, Tanis, BC, van den Bosch, MA, Bollen, EL, Helmerhorst, FM, van der Graaf, Y, et al. (2002). Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke, 33(5), 1202–08.Google Scholar

Kernan, WN, Ovbiagele, B, Black, HR, Bravata, DM, Chimowitz, MI, Ezekowitz, MD, et al. (2014). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45(7), 2160–2236.Google Scholar

Khoury, JC, Kleindorfer, D, Alwell, K, Moomaw, CJ, Woo, D, Adeoye, O, et al. (2013). Diabetes mellitus: a risk factor for ischemic stroke in a large biracial population. Stroke, 44(6), 1500–04.Google Scholar

Kodama, S, Saito, K, Tanaka, S, Horikawa, C, Saito, A, Heianza, Y, et al. (2011). Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol, 57(4), 427–36.Google Scholar

Kwok, CS, Pradhan, A, Khan, MA, Anderson, SG, Keavney, BD, Myint, PK, et al. (2014). Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol, 173(1), 20–8.Google Scholar

Larsson, SC, Wallin, A, Wolk, A, Markus, HS. (2016). Differing association of alcohol consumption with different stroke types: a systematic review and meta-analysis. BMC Med, 14(1), 178.Google Scholar

Lee, HJ, Choi, EK, Lee, SH, Kim, YJ, Han, D, Oh, S. (2018). Risk of ischemic stroke in metabolically healthy obesity: a nationwide population-based study. PLoS One, 13(3), e0195210.Google Scholar

Lee, M, Saver, JL, Hong, KS, Song, S, Chang, KH, Ovbiagele, B. (2012). Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ, 344, e3564.Google Scholar

Lee, PN, Forey, BA. (2006). Environmental tobacco smoke exposure and risk of stroke in nonsmokers: a review with meta-analysis. J Stroke Cerebrovasc Dis, 15(5), 190–201.Google Scholar

Li XY, Cai XL, Bian PD, Hu LR. (2012). High salt intake and stroke: meta-analysis of the epidemiologic evidence. CNS Neurosci Ther, 18(8), 691–701.Google Scholar

Lin, MP, Ovbiagele, B, Markovic, D, Towfighi, A. (2016). Association of secondhand smoke with stroke outcomes. Stroke, 47(11), 2828–35.Google Scholar

Liyanage, T, Ninomiya, T, Wang, A, Neal, B, Jun, M, Wong, MG, et al. (2016). Effects of the Mediterranean Diet on cardiovascular outcomes – a systematic review and meta-analysis. PLoS One, 11(8), e0159252.Google Scholar

Lloyd-Jones, DM, Hong, Y, Labarthe, D, Mozaffarian, D, Appel, LJ, Van Horn, L, et al. (2010). Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation, 121(4), 586–613.Google Scholar

Malek, AM, Cushman, M, Lackland, DT, Howard, G, McClure, LA. (2015). Secondhand smoke exposure and stroke: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Prev Med, 49(6), e89–97.Google Scholar

Marso, SP, Kennedy, KF, House, JA, McGuire, DK. (2010). The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res, 7(2), 119–30.Google Scholar

Marti-Carvajal, AJ, Sola, I, Lathyris, D, Dayer, M. (2017). Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev, 8. CD006612.Google Scholar

Martinez-Gonzalez, MA, Dominguez, LJ, Delgado-Rodriguez, M. (2014). Olive oil consumption and risk of CHD and/or stroke: a meta-analysis of case-control, cohort and intervention studies. Br J Nutr, 112(2), 248–59.Google Scholar

McRobbie, H, Bullen, C, Hartmann-Boyce, J, Hajek, P. (2014). Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev, 12. CD010216.Google Scholar

Meschia, JF, Bushnell, C, Boden-Albala, B, Braun, LT, Bravata, DM, Chaturvedi, S, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. (2014). Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45(12), 3754–3832.Google Scholar

Moresoli, P, Habib, B, Reynier, P, Secrest, MH, Eisenberg, MJ, Filion, KB. (2017). Carotid stenting versus endarterectomy for asymptomatic carotid artery stenosis: a systematic review and meta-analysis. Stroke, 48(8), 2150–7.Google Scholar

Mukamal, KJ, Massaro, JM, Ault, KA, Mittleman, MA, Sutherland, PA, Lipinska, I, (2005). Alcohol consumption and platelet activation and aggregation among women and men: the Framingham Offspring Study. Alcohol Clin Exp Res, 29(10), 1906–12.Google Scholar

Myung, SK, Ju, W, Cho, B, Oh, SW, Park, SM, Koo, BK, Park, BJ, and Korean Meta-Analysis Study Group. (2013). Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ, 346, f10.Google Scholar

Narain, A, Kwok, CS, Mamas, MA. (2016). Soft drinks and sweetened beverages and the risk of cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Clin Pract, 70(10), 791–805.Google Scholar

Ndanuko, RN, Tapsell, LC, Charlton, KE, Neale, EP, Batterham, MJ. (2016). Dietary patterns and blood pressure in adults: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr, 7(1), 76–89.Google Scholar

Nightingale, AL, Farmer, RD. (2004). Ischemic stroke in young women: a nested case-control study using the UK General Practice Research Database. Stroke, 35(7), 1574–8.Google Scholar

O’Donnell, MJ, Chin, SL, Rangarajan, S, Xavier, D, Liu, L, Zhang, H, et al.; and INTERSTROKE Investigators. (2016). Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet, 388(10046), 761–75.Google Scholar

Oesch, L, Tatlisumak, T, Arnold, M, Sarikaya, H. (2017). Obesity paradox in stroke – myth or reality? A systematic review. PLoS One, 12(3), e0171334.Google Scholar

Oono, IP, Mackay, DF, Pell, JP. (2011). Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf), 33(4), 496–502.Google Scholar

Pan, A, Wang, Y, Talaei, M, Hu, FB. (2015). Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation, 132(19), 1795–1804.Google Scholar

Peters, SA, Huxley, RR, Woodward, M. (2013). Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke, 44(10), 2821–8.Google Scholar

Peters, SA, Huxley, RR, Woodward, M. (2014). Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet, 383(9933), 1973–80.Google Scholar

Qin, X, Li, J, Spence, JD, Zhang, Y, Li, Y, Wang, X, et al. (2016). Folic acid therapy reduces the first stroke risk associated with hypercholesterolemia among hypertensive patients. Stroke, 47(11), 2805–12.Google Scholar

Roach, RE, Helmerhorst, FM, Lijfering, WM, Stijnen, T, Algra, A, Dekkers, OM. (2015). Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev, 8. CD011054.Google Scholar

Roberson, LL, Aneni, EC, Maziak, W, Agatston, A, Feldman, T, Rouseff, M, et al. (2014). Beyond BMI: the metabolically healthy obese phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review. BMC Public Health, 14, 14.Google Scholar

Rothwell, PM, Eliasziw, M, Gutnikov, SA, Fox, AJ, Taylor, DW, Mayberg, MR, et al. (2003). Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet, 361(9352), 107–16.Google Scholar

Sabatine, MS, Leiter, LA, Wiviott, SD, Giugliano, RP, Deedwania, P, De Ferrari, GM, et al. (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol, 5(12), 941–50.Google Scholar

Sackner-Bernstein, J, Kanter, D, Kaul, S. (2015). Dietary intervention for overweight and obese adults: comparison of low-carbohydrate and low-fat diets. a meta-analysis. PLoS One, 10(10), e0139817.Google Scholar

Samson, JE, Tanner-Smith, EE. (2015). Single-session alcohol interventions for heavy drinking college students: a systematic review and meta-analysis. J Stud Alcohol Drugs, 76(4), 530–43.Google Scholar

Santos, FL, Esteves, SS, da Costa Pereira, A, Yancy, WS Jr, Nunes, JP. (2012). Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev, 13(11), 1048–66.Google Scholar

Sattar, N, Preiss, D, Murray, HM, Welsh, P, Buckley, BM, de Craen, AJ, et al. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), 735–42.Google Scholar

Schwingshackl, L, Bogensberger, B, Hoffmann, G. (2018). Diet quality as assessed by the Healthy Eating Index, Alternate Healthy Eating Index, Dietary Approaches to Stop Hypertension Score, and Health Outcomes: an updated systematic review and meta-analysis of cohort studies. J Acad Nutr Diet, 118(1), 74–100 e111.Google Scholar

Schwingshackl, L, Hoffmann, G. (2014). Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. Lipids Health Dis, 13, 154.Google Scholar

Shah, RS, Cole, JW. (2010). Smoking and stroke: the more you smoke the more you stroke. Expert Rev Cardiovasc Ther, 8(7), 917–32.Google Scholar

Shou, J, Zhou, L, Zhu, S, Zhang, X. (2015). Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis, 24(9), 1961–8.Google Scholar

Siebenhofer, A, Jeitler, K, Horvath, K, Berghold, A, Posch, N, Meschik, J, et al. (2016). Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev, 3. CD007654.Google Scholar

Spence, JD, Yi, Q, Hankey, GJ. (2017). B vitamins in stroke prevention: time to reconsider. Lancet Neurol, 16(9), 750–60.Google Scholar

Stead, LF, Buitrago, D, Preciado, N, Sanchez, G, Hartmann-Boyce, J, Lancaster, T. (2013). Physician advice for smoking cessation. Cochrane Database Syst Rev, 5. CD000165.Google Scholar

Stead, LF, Koilpillai, P, Lancaster, T. (2015). Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev, 10. CD009670.Google Scholar

Stead, LF, Perera, R, Bullen, C, Mant, D, Hartmann-Boyce, J, Cahill, K, et al. (2012). Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 11. CD000146.Google Scholar

Strazzullo, P, D’Elia, L, Cairella, G, Garbagnati, F, Cappuccio, FP, Scalfi, L. (2010). Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke, 41(5): e418–26.Google Scholar

Threapleton, DE, Greenwood, DC, Evans, CE, Cleghorn, CL, Nykjaer, C, Woodhead, C, et al. (2013). Dietary fiber intake and risk of first stroke: a systematic review and meta-analysis. Stroke, 44(5), 1360–8.Google Scholar

Tian, DY, Tian, J, Shi, CH, Song, B, Wu, J, Ji, Y, et al. (2015). Calcium intake and the risk of stroke: an up-dated meta-analysis of prospective studies. Asia Pac J Clin Nutr, 24(2), 245–52.Google Scholar

Towfighi, A, Markovic, D, Ovbiagele, B. (2012a). Current national patterns of comorbid diabetes among acute ischemic stroke patients. Cerebrovasc Dis, 33(5), 411–18.Google Scholar

Towfighi, A, Markovic, D, Ovbiagele, B. (2012b). Impact of a healthy lifestyle on all-cause and cardiovascular mortality after stroke in the USA. J Neurol Neurosurg Psychiatry, 83(2), 146–151.Google Scholar

Towfighi, A, Ovbiagele, B. (2009). The impact of body mass index on mortality after stroke. Stroke, 40(8), 2704–08.Google Scholar

Vinceti, M, Filippini, T, Crippa, A, de Sesmaisons, A, Wise, LA, Orsini, N. (2016). Meta-analysis of potassium intake and the risk of stroke. J Am Heart Assoc, 5(10), e004210.Google Scholar

Wahid, A, Manek, N, Nichols, M, Kelly, P, Foster, C, Webster, P, et al. (2016). Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc, 5(9).Google Scholar

Whiting, DR, Guariguata, L, Weil, C, Shaw, J. (2011). IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract, 94(3), 311–21.Google Scholar

Wilk, AI, Jensen, NM, Havighurst, TC. (1997). Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. J Gen Intern Med, 12(5), 274–83.Google Scholar

Woodward, M, Lam, TH, Barzi, F, Patel, A, Gu, D, Rodgers, A, et al., and Asia Pacific Cohort Studies Collaboration. (2005). Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol, 34(5), 1036–45.Google Scholar

Wu, O, Robertson, L, Twaddle, S, Lowe, GD, Clark, P, Greaves, M, et al. (2006). Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess, 10(11), 1–110.Google Scholar

Xu, L, Lam, TH, Jiang, CQ, Zhang, WS, Zhu, F, Jin, YL, et al. (2019). Egg consumption and the risk of cardiovascular disease and all-cause mortality: Guangzhou Biobank Cohort Study and meta-analyses. Eur J Nutr, 58(2), 785–96.Google Scholar

Xu, Z, Li, Y, Tang, S, Huang, X, Chen, T. (2015). Current use of oral contraceptives and the risk of first-ever ischemic stroke: a meta-analysis of observational studies. Thromb Res, 136(1), 52–60.Google Scholar

Yang, C, Pan, L, Sun, C, Xi, Y, Wang, L, Li, D. (2016). Red meat consumption and the risk of stroke: a dose-response meta-analysis of prospective cohort studies. J Stroke Cerebrovasc Dis, 25(5), 1177–86.Google Scholar

Yuan, S, Li, X, Jin, Y, Lu, J. (2017). Chocolate consumption and risk of coronary heart disease, stroke, and diabetes: a meta-analysis of prospective studies. Nutrients, 9(7):688. doi: 10.3390/nu9070688.Google Scholar

Zhang, C, Qin, YY, Wei, X, Yu, FF, Zhou, YH, He, J. (2015). Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies. Eur J Epidemiol, 30(2), 103–13.Google Scholar

Zhao, M, Wu, G, Li, Y, Wang, X, Hou, FF, Xu, X, et al. (2017). Meta-analysis of folic acid efficacy trials in stroke prevention: insight into effect modifiers. Neurology, 88(19), 1830–8.Google Scholar

Zhong, CK, Zhong, XY, Xu, T, Zhang, YH. (2016). Measures of abdominal adiposity and risk of stroke: a dose-response meta-analysis of prospective studies. Biomed Environ Sci, 29(1), 12–23.Google Scholar

Zoungas, S, Arima, H, Gerstein, HC, Holman, RR, Woodward, M, Reaven, P, et al.; Collaborators on Trials of Lowering Glucose. (2017). Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol, 5(6), 431–7.Google Scholar

ACTIVE Investigators. (2009). Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med, 360, 2066–78.Google Scholar

Albertsen, IE, Rasmussen, LH, Overvad, TF, Graungaard, T, Larsen, TB, Lip, GY. (2013). Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke, 44, 1329–36.Google Scholar

Alli, OO, Holmes, DR Jr. (2015). Left atrial appendage occlusion for stroke prevention. Curr Probl Cardiol, 40, 429–76.Google Scholar

Almekhlafi, MA, Wilton, SB, Rabi, DM, Ghali, WA, Lorenzetti, DL, Hill, MD. (2009). Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology, 73, 89–97.Google Scholar

Ansell, JE, Bakhru, SH, Laulicht, BE, Steiner, SS, Grosso, M, Brown, K, et al. (2014). Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med, 371, 2141–2Google Scholar

Baddour, LM, Wilson, WR, Bayer, AS, Fowler, VG Jr, Tleyjeh, IM, Rybak, MJ, et al. (2015) Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation, 132, 1435–86.Google Scholar

Bala, MM, Paszek, E, Lesniak, W, Wloch-Kopec, D, Jasinska, K, Undas, A. (2018) Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst Rev, 7, CD012534.Google Scholar

Beyer-Westendorf, J, Forster, K, Pannach, S, Ebertz, F, Gelbricht, V, Thieme, C, et al. (2014). Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood, 124, 955–962.Google Scholar

Borre, ED, Goode, A, Raitz, G, Shah, B, Lowenstern, A, Chatterjee, R, et al. (2018). Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost, 118, 2171–87.Google Scholar

Bruins Slot, KM, Berge, E. (2018). Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev, 3, CD008980. doi:10.1002/14651858.CD008980.pub3.Google Scholar

Cannon, CP, Bhatt, DL, Oldgren, J, Lip, GYH, Ellis, SG, Kimura, T, et al.; RE-DUAL PCI Steering Committee and Investigators. (2017). Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med, 377, 1513–24.Google Scholar

Chandrashekhar, Y, Westaby, S, Narula, J. (2009) Mitral stenosis. Lancet, 374, 1271–83.Google Scholar

Chen, LY, Norby, FL, Chamberlain, AM, MacLehose, RF, Bengtson, LG, Lutsey, PL, et al. (2019). CHA₂DS₂-VASc score and stroke prediction in atrial fibrillation in whites, blacks and Hispanics. Stroke, 50, 28–33.Google Scholar

Chi, G, Kerneis, M, Kalayci, A, Liu, Y, Mehran, R, Bode, C, et al (2018). Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. Am Heart J, 203,17–24.Google Scholar

Connolly, SJ, Pogue, J, Eikelboom, J, Flaker, G, Commerford, P, Franzosi, MG, et al. (2008). Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation, 118, 2029–37.Google Scholar

Connolly, SJ, Ezekowitz, MD, Yusuf, S, Eikelboom, J, Oldgren, J, Parekh, A, et al., for the RE-LY Steering Committee and Investigators. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 361, 1139–51.Google Scholar

Connolly, SJ, Ezekowitz, MD, Yusuf, S, Reilly, PA, Wallentin, L, for the Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. (2010). Newly identified events in the RE-LY trial (letter to the editor). N Engl J Med, 363, 1875–6.Google Scholar

Connolly, SJ, Eikelboom, JW, Ng, J, Hirsh, J, Yusuf, S, Pogue, J, et al., and the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. (2011a). Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med, 155, 579–86.Google Scholar

Connolly, SJ, Eikelboom, J, Joyner, C, Diener, HC, Hart, R, Golitsyn, S, et al., and the AVERROES Steering Committee and Investigators. (2011b). Apixaban in patients with atrial fibrillation. N Engl J Med, 364, 806–17.Google Scholar

Connolly, SJ, Milling, TJ, Eikelboom, JW, Gibson, CM, Curnutte, JT, Gold, A, et al., ANNEXA-4 Investigators. (2016). Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med, 375, 1131–41.Google Scholar

Connolly, SJ, Crowther, M, Eikelboom, JW, Gibson, CM, Curnutte, JT, Lawrence, JH, et al; ANNEXA-4 Investigators. (2019). Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N Engl J Med, 380, 1326–35.Google Scholar

Das, A, Liu, D. (2015). Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol, 4, 25.Google Scholar

DeWilde, WJ, Oirbans, T, Verheugt, FW, Kelder, JC, De Smet, JP, Adriaenssens, T, et al.; WOEST Study Investigators. (2013). Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet, 381, 1107–15.Google Scholar

Di Biase, L, Santangeli, P, Anselmino, M, Mohanty, P, Salvetti, I, Gili, S, et al. (2012). Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol, 60, 531–8.Google Scholar

Diener, HC, Eikelboom, J, Connolly, SJ, Joyner, CD, Hart, RG, Lip, GY, et al.; AVERROES Steering Committee and Investigators. (2012). Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomized trial. Lancet Neurol, 11, 225–31.Google Scholar

Douketis, JD, Spyropoulos, AC, Kaatz, S, Becker, RC, Caprini, JA, Dunn, AS, et al.; BRIDGE Investigators. (2015). Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med, 373, 823–33.Google Scholar

Eikelboom, JW, Connolly, SJ, Brueckmann, M, Granger, CB, Kappetein, AP, Mack, MJ, et al.; RE-ALIGN Investigators. (2013). Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med, 369, 1206–14.Google Scholar

Eikelboom, JW, Quinlan, DJ, van Ryn, J, Weitz, JI. (2015). Idarucizumab: the antidote for reversal of dabigatran. Circulation, 132, 2412–22.Google Scholar

European Atrial Fibrillation Trial Study Group. (1993). Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet, 342, 1255–62.Google Scholar

Freudenberger, RS, Hellkamp, AS, Halperin, JL, Poole, J, Anderson, J, Johnson, G, et al. (2007). Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation, 115, 2637–41.Google Scholar

Friberg, L, Rosenqvist, M, Lip, GY. (2012). Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J, 33, 1500–10.Google Scholar

Gibson, CM, Mehran, R, Bode, C, Halperin, J, Verheugt, FW, Wildgoose, P, et al. (2016). Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med, 375, 2423–34.Google Scholar

Giugliano, RP, Ruff, CT, Braunwald, E, Murphy, SA, Wiviott, SD, Halperin, JL, et al.; ENGAGE AF-TIMI 48 Investigators. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 369, 2093–104.Google Scholar

Giugliano, RP, Ruff, CT, Rost, NS, Silverman, S, Wiviott, SD, Lowe, C, et al.; ENGAGE AF-TIMI 48 Investigators. (2014). Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke, 45, 2372–8.Google Scholar

Gladstone, DJ, Spring, M, Dorian, P, for the EMBRACE Investigators and Coordinators. (2014). Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med, 370, 2467–77.Google Scholar

Glund, S, Stangier, J, Schmohl, M, Gansser, D, Norris, S, van Ryn, J, et al. (2015). Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet, 386, 680–90.Google Scholar

Goldberger, JJ, Arora, R, Green, D, Greenland, P, Lee, DC, Lloyd-Jones, DM, et al. (2015). Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. Circulation, 132, 278–91.Google Scholar

Goldstein, JN, Refaai, MA, Milling, TJ Jr, Lewis, B, Goldberg-Alberts, R, Hug, BA, et al. (2015). Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet, 385, 2077–87.Google Scholar

Gosselin, RC, Adcock, DM, Bates, SM, Douxfils, J, Favaloro, EJ, Gouin-Thibault, I, et al., International Council for Standardization in Haematology (ICSH). (2018). Recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost, 118, 437–50.Google Scholar

Granger, CB, Alexander, JH, McMurray, JJV, Lopes, RD, Hylek, EM, Hanna, M, et al., for the ARISTOTLE Committees and Investigators. (2011). Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 365, 981–92.Google Scholar

Gurol, ME. (2018). Nonpharmacological management of atrial fibrillation in patients at high intracranial hemorrhage risk. Stroke, 49, 247–254.Google Scholar

Hankey, GJ, Patel, MR, Stevens, SR, Becker, RC, Breithardt, G, Carolei, A, et al.; ROCKET AF Steering Committee Investigators. (2012). Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol, 11, 315-22.Google Scholar

Hankey, GJ, McQuillan, BM. (2018). Patent foramen ovale closure: the pendulum swings. Circulation, 137, 1991–3.Google Scholar

Hankey, GJ, Stevens, SR, Piccini, JP, Lokhnygina, Y, Mahaffey, KW, Halperin, JL, et al.; ROCKET AF Steering Committee and Investigators. (2014). Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke, 45, 1304–12.Google Scholar

Hanif, H, Belley-Cote, EP, Alotaibi, A, Dvirnik, N, Neupane, B, Beyene, J, et al. (2018). Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. J Cardiovasc Surg (Torino), 59, 128–39.Google Scholar

Hart, RG, Diener, HC, Yang, S, Connolly, SJ, Wallentin, L, Reilly, PA, et al. (2012). Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke, 43, 1511–17.Google Scholar

Hart, RG, Pearce, LA, Aguilar, MI. (2007). Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 146, 857–67.Google Scholar

Healey, JS, Eikelboom, J, Douketis, J, Wallentin, L, Oldgren, J, Yang, S, et al. (2012). Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long- Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation, 126, 343–8.Google Scholar

Healey, JS, Hart, RG, Pogue, J, Pfeffer, MA, Hohnloser, SH, De Caterina, R, et al. (2008). Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke, 39, 1482–6.Google Scholar

Heidbuchel, H, Verhamme, P, Alings, M, Antz, M, Hacke, W, Oldgren, J, et al.; European Heart Rhythm Association. (2013). European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 15, 625–51.Google Scholar

Heidbuchel, H, Verhamme, P, Alings, M, Antz, M, Diener, HC, Hacke, W, et al.; ESC Scientific Document Group. (2017) Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J, 38, 2137–49.Google Scholar

Heo, YA. (2018). Andexanet alfa: first global approval. Drugs, 78, 1049–55.Google Scholar

Hijazi, Z, Lindbäck, J, Alexander, JH, Hanna, M, Held, C, Hylek, EM, et al., for the ARISTOTLE and STABILITY Investigators. (2016a). The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J, 37, 1582–90.Google Scholar

Hijazi, Z, Oldgren, J, Lindbäck, J, Alexander, JH, Connolly, SJ, Eikelboom, JW, et al., for the ARISTOTLE and RE-LY Investigators. (2016b). The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, 387, 2302–11.Google Scholar

Homma, S, Sacco, RL, Di Tullio, MR, Sciacca, RR, Mohr, JP; PFO In Cryptogenic Stroke Study (PICSS) Investigators. (2002). Effect of medical treatment in stroke patients with patent foramen ovale: Patent foramen ovale In Cryptogenic Stroke Study. Circulation, 105, 2625–31.Google Scholar

Huang, WY, Singer, DE, Wu, YL, Chiang, CE, Weng, HH, Lee, M, et al. (2018). Association of intracranial haemorrhage risk with non-vitamin K antagonist oral anticoagulant use vs aspirin use. A systematic review and meta-analysis. JAMA Neurol, 75, 1511–18.Google Scholar

Idarucizumab (Praxbind) – an antidote for dabigatran. (2015). Med Lett Drugs Ther, 57, 157–8.Google Scholar

Iversen, K, Ihlemann, N, Gill, SU, Madsen, T, Elming, H, Jensen, KT, et al. (2019). Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med, 380, 415–24.Google Scholar

Jonas, DE, Kahwati, LC, Yun, JDY, Middleton, JC, Coker-Schwimmer, M, Asher, GN. (2018). Screening for atrial fibrillation with electrocardiography: evidence report and systematic review for the US Preventive Services Task Force. JAMA, 320, 485–98.Google Scholar

Kasner, SE, Swaminathan, B, Lavados, P, Sharma, M, Muir, K, Veltkamp, R, et al.; NAVIGATE ESUS Investigators. (2018). Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol, 17, 1053–60.Google Scholar

Kernan, WN, Ovbiagele, B, Black, HR, Bravata, DM, Chimowitz, MI, Ezekowitz, MD, et al. (2014). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45, 2160–236.Google Scholar

Kontny, F, Dale, J, Abildgaard, U, Pedersen, TR. (1997). Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol, 30,962–9.Google Scholar

Kuijpers, T, Spencer, FA, Siemieniuk, RAC, Vandvik, PO, Otto, CM, Lytvyn, L, et al. (2018). Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ, 362, k2515.Google Scholar

Leyden, JM, Kleinig, TJ, Newbury, J, Castle, S, Cranefield, J, Anderson, CS, et al. (2013). Adelaide Stroke Incidence Study: declining stroke rates but many preventable cardioembolic strokes. Stroke, 44, 1226–31.Google Scholar

Lindahl, TL, Wallstedt, M, Gustafsson, KM, Persson, E, Hillarp, A. (2015). More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. Thromb Res, 135, 544–7.Google Scholar

Lip, GY, Nieuwlaat, R, Pisters, R, Lane, DA, Crijns, HJ. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in AF using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest, 137, 263–72.Google Scholar

Lowenstern, A, Al-Khatib, SM, Sharan, L, Chatterjee, R, Allen LaPointe, NM, Shah, B, et al. (2018). Interventions for preventing thromboembolic events in people with atrial fibrillation. A systematic review. Ann Intern Med, 169, 774–87.Google Scholar

Lu, G, DeGuzman, FR, Hollenbach, SJ, Karbarz, MJ, Abe, K, Lee, G, et al. (2013). A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med, 19, 446–51.Google Scholar

Mahajan, N, Ganguly, J, Simegn, M, Bhattacharya, P, Shankar, L, Madhavan, R, et al. (2010). Predictors of stroke in patients with severe systolic dysfunction in sinus rhythm: role of echocardiography. Int J Cardiol, 145, 87–9.Google Scholar

Maheshwari, A, Norby, FL, Roetker, NS, Soliman, EZ, Koene, RJ, Rooney, MR, et al. (2019). Refining predictions of atrial fibrillation-related stroke using the P₂- CHA₂DS₂-VASc score. ARIC and MESA. Circulation, 139,180–91.Google Scholar

Majeed, A, Agren, A, Holmstrom, M, Bruzelius, M, Chaireti, R, Odeberg, J, et al. (2017). Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood, 130,1706–12Google Scholar

Mas, JL, Arquizan, C, Lamy, C, Zuber, M, Cabanes, L, Derumeaux, G, et al., and the Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. (2001). Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med, 345, 1740–6.Google Scholar

Mas, JL, Derumeaux, G, Guillon, B, Massardier, E, Hosseini, H, Mechtouff, L, et al., CLOSE Investigators. (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med, 377, 1011–21.Google Scholar

Massel, DR, Little, SH. (2013). Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev, 7, CD003464. doi:10.1002/14651858.CD003464.pub2.Google Scholar

Mazzucco, S, Li, L, Binney, L, Rothwell, PM; Oxford Vascular Study Phenotyped Cohort. (2018). Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis. Lancet Neurol; 17, 609–17.Google Scholar

McGrath, ER, Kapral, MK, Fang, J, Eikelboom, JW, o Conghaile, A, Canavan, M, et al., and the Investigators of the Registry of the Canadian Stroke Network. (2012). Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation? Stroke, 43, 2048–54.Google Scholar

Merkler, AE, Gialdini, G, Yaghi, S, Okin, PM, Iadecola, C, Navi, BB, Kamel, H. (2017). Safety outcomes after percutaneous transcatheter closure of patent foramen ovale. Stroke, 48, 3073–7.Google Scholar

Mir, H, Siemieniuk, RAC, Ge, LC, Foroutan, F, Fralick, M, Syed, T, et al (2018). Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open, 8, e023761.Google Scholar

Nishimura, RA, Otto, CM, Bonow, RO, Carabello, BA, Erwin, JP 3rd, Guyton, RA, et al. (2014). 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129, 2440–92.Google Scholar

Ng, KKH, Whiteley, W. (2017). Anticoagulation timing for atrial fibrillation in acute ischemic stroke: time to reopen Pandora’s box? JAMA Neurol, 74, 1174–5.Google Scholar

Ntaios, G, Papavasileiou, V, Diener, HC, Makaritsis, K, Michel, P. (2017). Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke, 12, 589–96.Google Scholar

Ntaios, G, Papavasileiou, V, Sagris, D, Makaritsis, K, Vemmos, K, Steiner, T, Michel, P. (2018). Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack: updated systematic review and meta-analysis. Stroke, 49, 412–18.Google Scholar

Oldgren, J, Alings, M, Darius, H, Diener, HC, Eikelboom, J, Ezekowitz, MD, et al., and the RE-LY Investigators. (2011). Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med, 155, 660–7.Google Scholar

Olesen, JB, Lip, GY, Hansen, ML, Tolstrup, JS, Lindhardsen, J, Selmer, C, et al. (2011). Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: a nationwide cohort study. BMJ, 342, d124.Google Scholar

Patel, MR, Mahaffey, KW, Garg, J, Pan, G, Singer, DE, Hacke, W, et al., for the ROCKET AF Investigators. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 365, 883–91.Google Scholar

Pisters, R, Lane, DA, Nieuwlaat, R, de Vos, CB, Crijns, HJ, Lip, GY. (2010). A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in AF patients: the Euro Heart Survey. Chest, 138, 1093–100.Google Scholar

Pollack, CV Jr, Reilly, PA, Eikelboom, J, Glund, S, Verhamme, P, Bernstein, RA, et al. (2015). Idarucizumab for Dabigatran Reversal. N Engl J Med. 373, 511–20.Google Scholar

Pollack, CV Jr, Reilly, PA, van Ryn, J, Eikelboom, JW, Glund, S, Bernstein, RA, et al. (2017). Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med, 377, 431–41.Google Scholar

Powers, WJ. (2018) Additional factors in considering patent foramen ovale closure to prevent recurrent ischemic stroke. JAMA Neurol, 75, 895.Google Scholar

Reddy, VY, Sievert, H, Halperin, J, Doshi, SK, Buchbinder, M, Neuzil, P, et al., PROTECT AF Steering Committee and Investigators. (2014). Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA, 312, 1988–98.Google Scholar